Online Livestreaming  Date: June 17-18, 2021 On June 17-18 2021, medical affairs professionals are invited to attend DGE’s 2nd Annual Medical Affairs Leadership Forum to learn successful strategies to derive the maximum out of their work environment, increase job satisfaction, and create a work-life balance. The event is hosted by Dynamic Global Events (“DGE”), a life science leader in organizing B2B events. The world-class event company is an industry trailblazer, meeting the evolving informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical device, and allied industries. Medical Affairs professionals are entrusted with the task of being productive to the organization and putting their company ahead of the competition. This becomes a mammoth task if they do not find their jobs fulfilling and are insecure about the future of their role in the company. This 2-day online event offers a successful platform for medical professionals to interact with co-workers and people working in the medical realm and to explore the career opportunities and challenges faced in this profession. The event will witness speeches, discussions, and opinions of a distinguished panel of speakers from the medical fraternity. Life science professionals can register to attend the live streaming 2021 Medical Affairs Leadership Forum that will offer:

• New career opportunities for professionals dealing in medical affairs
• An insight on the role of medical affairs professionals in the Virtual environment
• Ways to create a positive work atmosphere and increase work productivity
• Strategies of dealing with work-related stress
• Tips and expertise required to develop a successful MLS career

The COVID-19 impact has brought forth an unexpected paradigm shift in the responsibilities of medical affairs professionals. The world-class speaking faculty will present their views and discuss the changes in the work environment and how professionals will need to adjust to it. Attendees can learn about how in-person meetings will be replaced by virtual team meetings for medical affairs post COVID, and discuss their impact on inter-departmental collaboration in a digital scenario while learning the best ways to complete assignments. The main focus of the event is to ensure the growth of professionals in the medical affairs arena which is foundational for leadership and success. For tickets to the event, please visit https://ibn.fm/cEwVf

Date: June 8-11, 2021 Virtual Conference The Influencer Marketing Strategies Summit will be held from June 8-10, 2021. Brands, marketers, entrepreneurs, investors, and individuals looking to grow their online presence are invited to attend this virtual event. This global Summit is a one-of-a-kind event that will cover an entire spectrum of topics to launch, scale, and measure influencer programs. The event is co-hosted with Social Media Strategies Summit. The Summit will witness keynotes and discussion sessions from experienced speakers who are well-known influencers in their niche area. Marketers can get their influencer queries answered in the Q&A Sessions and learn strategies to elevate their brand’s influencer marketing campaigns. The virtual conference will cover topics that will help businesses understand how to integrate their digital efforts and business goals with their influencer marketing plans. Influencers and eminent social media persons from all over the globe will share their experiences, giving lessons of transparency and accountability to the attendees. The session’s agenda includes:

• A well-explained session on how to create meaningful video content
• A discussion on how influencers are growing in their reach and impact
• How and when should influencers take a stance on brand activism
• Working with influencers on the Tiktok platform
• Finding a long-term influencer who represents your brand
• Integrating AI into high-powered influencer marketing campaigns
• Changes made in the strategies and execution of influencer marketing campaigns post COVID
• Constant evaluation of parameters of influencer marketing to ensure brand safety

The 4-day session a wonderful learning experience to broaden your digital and business perspective and help brands take the necessary steps to design a winning influencer campaign. With over 10 years of experience in digital marketing and influencer marketing, the Influencer Marketing Strategies Summit offers a global platform to learn and engage with marketing leaders and decision-makers of influencer marketing. Attendees will immensely benefit from the curated series of sessions on the latest digital marketing topics and influencer campaigns that they can align with their brand marketing strategies. To know more about the event, please visit https://ibn.fm/YZw0W

• BAND Royalty has successfully bought the performance royalty rights to Justin Timberlake’s multi-platinum song “Mirrors”, along with the performance royalty rights to 50+ other songs performed by JayZ, Beyonce, Timbaland, Cher, Demi Lovato, and many more. in a bold move they are giving anyone the ability to enter the secretive world of royalty investing by letting them share in the revenue from these royalty rights when they buy a BAND Royalty NFT for as little as 1 Ethereum.
• NFTs are built like cryptocurrency, such as Bitcoin or Ethereum, but are non-fungible, meaning that they have a unique digital signature which makes them impossible to be counterfeited, damaged, or destroyed, guaranteeing full chain of custody.
• Jack Dorsey sold his first Tweet for over $2.9 million, and Beeple sold his digital artwork EVERYDAYS: THE FIRST 5000 DAYS for $69 million all through NFT.
• BAND Royalty’s Series 1 art-inspired music NFTs have a limited number still available for purchase, and showcase unique artwork highlighting diversification in the music industry.
• Company plans to release more tokens in the future.
• The minimum amount of time that a token can be staked is 90 days, topping out at a maximum of five years, and are subject to short-term capital gains taxing.

BAND Royalty is a music industry disruptor, the first to use NFTs (non-fungible tokens) to create the first-ever DeFi (decentralized finance) opportunity based on music royalties. Founded by and named after Barnaby Andersun (BA) and Noble Drakoln (ND), BAND Royalty is uniquely positioned in the industry to capitalize on the shifting landscape that surrounds digital ownership. NFTs are not a cryptocurrency, but interested buyers will need to invest in some cryptocurrency to purchase the ones available from BAND. Even though NFTs are built like cryptocurrency – Bitcoin or Ethereum – that is where the similarity ends. NFTs were created to be non-fungible, meaning that they have a unique digital signature making it impossible for these tokens to be exchanged for or equal to another. NFTs can represent tangible and non-tangible items, including:

• Art
• GIFs
• Collectibles
• Videos
• Sports Highlights
• Virtual Avatars
• Video Game Skins
• Designer Shoes
• Music

Even something as simple as a tweet makes the list of NFTs – with Twitter CEO Jack Dorsey making history when he sold his first Tweet for more than $2.9 million (https://ibn.fm/h3RR5). In May 2007, a digital artist that goes by the name Beeple set out to create a piece of artwork, adding pieces daily for 5,000 days. The collection of daily digital art is known as EVERYDAYS, and the pieces together are EVERYDAYS: THE FIRST 5000 DAYS. The work was sold as an NFT in an online auction for $69 million, on March 11, 2021 (https://ibn.fm/StBqw). While BAND offers no guarantee of the return on investment from these NFTs, it provides holders with the opportunity to share in performance rights of various artists and songs and earn royalty income every time a song in the company’s catalog is performed. The catalog consists of songs by reputed artists including Beyonce, Cher, Rihanna, Missy Elliott, Jay-Z and more. Once they purchase the NFTs, users can stake them in one of three available pools: publishing, mechanical/public performance, and synchronization. The minimum amount of time that a token can be staked is 90 days, topping out at a maximum of five years. These are subject to short-term capital gains taxing. Coming in July BAND hopes to makes it easy for those who that own BAND Royalty art NFTs to stake them and share in the royalty income. After purchasing one of the limited release BAND NFTs and staking it in one of three royalty pools, BAND Royalty hopes to allow stakers to have the following opportunities:

1. Earn 50% of all BAND Royalty music catalog revenue
2. Earn 5% on BAND NFTs traded on the company’s first-ever music only NFT marketplace
3. Earn 50% from all other auctions of single BAND music tracks sold
4. Earn 5% from re-selling music royalties on the BAND platform

The current NFT offering from BAND consists of 15 pieces of unique artwork that celebrates the diversity of the music industry as a whole. The total number of Series 1 NFTs will be limited to 3000 NFTS with eight distinctive rarity levels, it’s called a “bonding curve”, provided on a first-come-first-serve purchase and time released schedule, see website for details. NFTs are currently available on the BAND platform and start at 1 ETH. As the rarity increases, so does the price, going as high as 25 ETH, which has already been sold. BAND already plans to release more music art NFTs, most likely over the next twelve months. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

• FingerMotion (OTCQX: FNGR) a mobile data and services company, is developing additional value-added technologies to expand its user base to over 1 billion users in China and other regional markets
• FingerMotion’s Data Insights platform Sapientus delivers data-driven solutions to the insurance and financial services industries
• Sapientus entered into a services agreement with Pacific Life Re, a global life reinsurer to deliver more efficient and customized solutions to the wider insurance ecosystem

FingerMotion (OTCQX: FNGR) is a mobile payment and recharge platform serving markets in China, evolving rapidly by using core competencies. With offices in Hong Kong, Shanghai, and New York, FingerMotion is developing additional value-added technologies to expand its user base to over 1 billion users in China and other regional markets (https://ibn.fm/bzxCu). Globally, the Big Data market is estimated to be worth $42 billion. Presently, this thriving industry is largely dominated by China which brings together59.5% of the world’s Big Data experts. Big Data is now being used in several industries in China namely retail, transport, government, health, and education. And though China has the largest Big Data manpower, it still has a significant need for data professionals (https://ibn.fm/NgrGK). The insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028 (https://ibn.fm/TGo7D). In addition, the shortage of data experts in China presents a huge opportunity for FingerMotion’s Data Insights platform Sapientus. Built to deliver data-driven and more refined solutions to the insurance and financial services industries, Sapientus’s Big Data offerings include risk scoring, targeted customer segmentation for precise marketing, simplified underwriting, and customizing products through granular persona analysis. FingerMotion has strategic alliances with the largest Chinese telecommunications names, thus having access to collect behavior insights through geolocation and mobile data usage. These insights offer data-driven solutions to clients who can in turn make discerning decisions and value creations based on the data provided. Recently, Sapientus entered into a services agreement with Pacific Life Re, a global life reinsurer offering a host of products and services to the insurance industry. With this alliance, the new insights from FingerMotion’s analytical Framework will be applied to the traditional insurance model. This multi-faceted risk rating concept will leverage the Company’s proprietary approach to analytics using advanced algorithms to offer more refined outcomes (https://ibn.fm/k5dPG). For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Friendable has ten successful months of growth with the Fan Pass platform, including an increase of 188% in new artist sign-ups since the beginning of the year.
• The company will be shifting all attention to its Fan Pass platform
• The global streaming video market was valued at $50.11 billion in 2020. This number is expected to grow at a CAGR of 21% through 2028.

Over the next 120 days and through the remainder of 2021, mobile technology and marketing company Friendable (OTC: FDBL) will be implementing a new strategy designed to ensure sustained and continued growth, consisting of the launch of an all-new corporate website, the V2 Fan Pass mobile and web applications, and a paid media campaign. After over ten months of successful operation and ongoing growth, the Fan Pass Livestream platform is advancing into the next phase of operations (https://ibn.fm/4CrCk). Fan Pass was launched in July 2020. Since the beginning of the year, Fan Pass has seen an increase of 188% of new artist sign-ups. In all significant parameters, the company has achieved double- and triple-digit growth. The launch of Fan Pass version two, is expected to continue promoting growth, with new innovative features for members, amid an increase in demand for services and artist acquisitions. “The success of the Fan Pass platform has always been based on this initial proof of concept and pilot phase, which has now been completed,” Friendable CEO Robert A. Rositano Jr. said. “I believe the v2 release of the all-new Fan Pass platform is going to blow our existing artists away and build a buzz through artist communities that will drive future growth, fan sign-ups, merchandise sales, and recurring revenue, all of which have been tested and proven at a micro level throughout our proof of concept and pilot phase.” Friendable wants to continue to build value in the business of live streaming and live event coordination for the foreseeable future and to accomplish this, it has set the following milestones as part of its 120-day strategy:

• New company/corporate website
• The sale of the Friendable dating app – transitioning 100% focus on the Fan Pass platform
• V2 Fan Pass beta testing completion for mobile and web application
• New tech tools for artists
• New mobile and web app deployment
• Paid media rollout for artists, fans, and public company awareness
• Social media influencer addition
• The rollout of the brand ambassador program
• Uplisting the company
• Building service and subscriber revenue as marketing campaigns scale and diversify
• Adding industry talents, partners, and BOD support
• Rolling out its NFT (non-fungible token) offering

Additional areas of growth and focus will be dedicated to driving downloads of the mobile app, the acquisition of exclusive content, artist performance, ticket sales, fee-based Pro Services, merch, fan subscriptions, recurring revenue, and adding a VIP Backstage Pass for those who cannot attend live events when venues are slated to reopen in late 2021-2022. One critical data point for Fan Pass is a Livestream/New York Magazine survey in which 45% of those who responded said that they would pay for live video from an artist, performer, speaker, or sports team. Eighty-seven percent of respondents said they would rather watch video online if it offered more behind-the-scenes content (https://ibn.fm/keQf7). Friendable is strategically leveraging its offering to insert itself in the middle of the global streaming video market that is valued at $50.11 billion in 2020 (https://ibn.fm/FYGa7). This number is expected to grow at a CAGR of 21% through 2028. With approximately 100 million users on the internet watching videos daily, the company is positioning itself to disrupt a highly lucrative market. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compounds
• Pharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trials
• The company intends to contribute to the growing body of research through academic collaborations with leading American institutions
• The research will focus on indications that other pharmaceutical companies have largely ignored

Although we can accurately describe the psychedelics industry as nascent, psychedelics have been the subject of a flurry of groundbreaking research that have gradually lifted the stigma surrounding their use. This ever-expanding body of research has proven the utility and efficacy of psychedelics in treating neuropsychiatric disease and improving mental health. The research-backed revival of the interest in psychedelics has led to the emergence of Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical developer founded in 2019, and other companies. Tryp focuses on producing novel bioscience solutions for conditions with unmet needs. Its current flagship program, Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”), involves the use of psychedelics. One of two drug development platforms, PFN^TM targets chronic pain conditions, including fibromyalgia, and eating disorders, and its lead drug candidate is TRP-8802. Tryp is leveraging existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 to proceed directly to Phase 2a clinical trials, in effect expediting drug development. The company is also looking to contribute to the ongoing research of psychedelics by collaborating with leading academic institutions. Already, Tryp has partnered with the University of Florida and lead investigator Jennifer Miller, M.D., for a Phase 2a clinical trial that will assess the efficacy and safety of TRP-8802 in treating eating disorders (https://ibn.fm/jsBVt). A professor of pediatrics and endocrinology, Miller has deep knowledge and expertise with eating disorders. In fact, as the director of the University of Florida Health’s Prader-Willi Syndrome (“PWS”) Program, she follows over 500 patients with PWS and more than 100 patients with early-onset obesity (https://ibn.fm/r9LVZ). Miller’s selection as the lead for the Phase 2a clinical trial is part of Tryp’s strategy to collaborate with principal investigators with deep understanding and knowledge of certain disease states. “We’ve been building a number of partnerships in the academic front,” said Tryp Chairman and CEO Greg McKee during an interview with Steve Darling from Proactive (https://ibn.fm/akAAv). “We’ve announced our relationship with the University of Florida. We’ve got several others that are in the works. We’ve got a deep conversation with a very well-known institution in the Midwest that we’ll be announcing shortly, we believe, and also two other conversations that we’ll soon be able to reveal; one with a significant academic collaborator in Southern California and a second conversation with an academic institution up in Northern California.” McKee described these institutions as having deep expertise in some particular fields, including two of the major areas Tryp is currently interested in: eating disorders (specifically hyperphagia, PWS, and binge eating) and chronic pain conditions (specifically fibromyalgia, complex regional pain syndrome, and phantom limb syndrome). “What’s important to us is that these are indications that no other company, at least up to this point, is going after and again, there’s great unmet medical need here and, we believe, a lot of room for new novel treatments,” McKee continued. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Cardiovascular disease is the leading cause of mortality among women globally and in the US
• Using this knowledge as the motivation, Healthy Extracts, through its wholly owned subsidiary BergaMet NA, developed HERHEART(TM)
• HERHEART is derived from the bergamot fruit, richly packed with polyphenols, and is formulated specifically for women to improve heart health and perimenopausal symptoms
• Polyphenols have antioxidant and anti-inflammatory properties and are associated with improved heart health, as well as the prevention of some heart-related conditions
• Through HERHEART product, Healthy Extracts is playing a vital preventative role in the fight against cardiovascular disease among women

Cardiovascular disease is the leading cause of death in women globally – it was the cause of 39% of all deaths in 2019 (https://ibn.fm/Rrnq8). In the US, this situation is still the same, with the Center for Disease Control noting that it accounted for 21.8% of the mortality in women of all ages, races, and origins in 2017; higher than cancer (20.7%). More dishearteningly, pregnancy predisposes women to cardiovascular disease even decades after delivery, mainly because of risk factors such as eclampsia, preeclampsia, gestational diabetes, and preterm delivery (https://ibn.fm/wcUUF). These reasons motivated BergaMet NA, a wholly owned subsidiary of Healthy Extracts (OTCQB: HYEX), to develop HERHEART(TM), an exclusive natural supplement scientifically formulated specifically for women to improve perimenopausal symptoms and cardiovascular health. It is derived from the Citrus Bergamot Superfruit(TM) (“bergamot”), which contains five unique antioxidant polyphenols in unusually concentrated amounts. It has a unique blend of flavonoids, a class of polyphenols, and glycosides. Polyphenols have been the subject of many scientific studies that have established their antioxidant, anti-platelet, and anti-inflammatory properties. Polyphenols are known for inhibiting the oxidation of low-density lipoproteins (“LDL”), which are sometimes referred to as bad cholesterol, in effect lowering the risk of developing atherosclerosis, a cardiovascular disease. They improve the function of endothelial cells – cells controlling the flow of fluid and substances into and out of cells from blood vessels – and increase high-density lipoproteins (“HDL”) or good cholesterol. Generally, polyphenols offer protection from hypertension, cancer, diabetes, aging, asthma, cardiovascular disease, and more (https://ibn.fm/25C57). Being a rich source of these vital compounds, BergaMet NA has used bergamot to develop a broad range of dietary supplement products geared towards heart and cholesterol health, including SPORTSHEART, HEART & CHOLESTEROL PRO+, HERHEART, CHOLESTEROL COMMAND, and CLINICAL IMMUNE (https://ibn.fm/ofRER). Notably, HERHEART stands out because of its significance in the fight against the leading cause of death among women. “HERHEART was specifically formulated to fill the void in heart health products specifically designed for women,” said Healthy Extracts President Duke Pitts in a press release announcing the results from a clinical study of HERHEART late last year. “Not only does HERHEART assist in metabolic syndrome challenges, but it also provides continued support for women as they mature. There is no other product that focuses directly on women, combines natural ingredients, and has the clinical studies to confirm its effectiveness.” The 2020 clinical study revealed that HERHEART reduced mood swings and hot flashes by 40% and 60%, respectively, increased energy by 45%, and improved arousal, comfort, and desire by between 40% and 70%. It also reduced cholesterol levels, acted as an anti-inflammatory agent, and metabolized fat. These findings are consistent with many other independent studies, particularly regarding the role of polyphenols in reducing bad cholesterol, as well as their anti-inflammatory property (https://ibn.fm/3SBPY). Dr. Nesochi Okeke-Igbokwe MD., M.S., a trusted and respected international health expert who recently joined HYEX’s Medical Advisory Board, recommends HERHEART to women as it addresses a host of health issues. “This is a supplement that is terrific for women of all ages and has a whole host of health benefits,” she stated. “What are these benefits? Studies have shown an improvement in heart health, cholesterol levels, mood, energy, and overall metabolism.” While the fight against cardiovascular disease among women also requires the input of medical practitioners who need to be more proactive in providing timely evidence-based treatment (https://ibn.fm/AE744), Healthy Extracts, through its subsidiary’s HERHEART supplement, is playing a key preventative role. For more information, visit the company’s website at www.HealthyExtractsInc.com. NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX About Healthy Extracts Inc. “Live Life Young Again” Healthy Extracts Inc. (OCTQB: HYEX) serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched. Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending. For more information, visit: www.healthyextractsinc.com or www.bergametna.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Healthy Extracts Inc. Las Vegas, Nevada www.healthyextractsinc.com info@healthyextractsinc.com 720-463-1004 Corporate Communications: InvestorBrandNetwork (“IBN”) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patients
• Wholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trial
• The company is planning the construction of a new lab and manufacturing space up to 32,000 square feet in Biberach, Germany
• Pilot project involving rapid COVID-19 PCR tests has been initiated in Germany, promising efficacy and accuracy of results in as little as 25 minutes
• XPhyto is currently in talks and negotiations with distribution and wholesale partners, with a potential sales launch in Europe during Q2 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, recently announced its 2021 drug formulation programs are on schedule and continue to expand in scope. The company’s drug formulation and development are conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH. Vektor is focused on the development of generic and hybrid-generic drug formulations for neurological conditions, with delivery platforms that include oral dissolvable and transdermal systems. The product pipeline targets large and growing markets with a promising potential for patient outcomes. A Q1 trial announced in January 2021 and focusing on a human bioavailability pilot study of the Rotigotine transdermal patch for Parkinson’s Disease was completed in March 2021. Due to the favorable outcome of the study, the Rotigotine development program will be advanced to include a pivotal human trial (https://ibn.fm/CFyAI). “Vektor continues to build shareholder value by advancing its product development pipeline. Its lead program is now progressing to a pivotal human study in Europe, which is the final major milestone on the path to commercial regulatory approval,” XPhyto CEO and Director Hugh Rogers explained. Also earlier this year, the company announced the intention to purchase a property in Biberach, Germany, where it plans to build a new commercial drug manufacturing facility. The estimated maximum capacity of the lab and manufacturing space permitted on the property is 3,000 square meters (32,000 square feet). Scalable construction options are being considered to synchronize manufacturing capacity with demand from both in-house and contractual opportunities. According to Rogers, the addition of in-house, scalable commercial drug manufacturing capability is expected to add further value and optionality to XPhyto’s drug formulation and manufacturing businesses. More details about the Rotigotine trial and the Biberach manufacturing facility construction will be made public in due course. XPhyto also announced that it recently commenced another pilot project with its rapid COVID-19 PCR test in a point-of-care setting in Germany. The test was recently approved in Europe and offers PCR test accuracy in only 25 minutes. During the pilot, validated workflows for the test, including mobile collection and processing of patient samples, will be optimized (https://ibn.fm/sDLKE). For this pilot project, XPhyto partnered with Spitzweg Apotheke, a well-known pharmacy in Langen, Germany, that is currently running a COVID-19 test center clinic and also provides specialized pharmaceutical services to cancer patients. “With a specialized oncology pharmacy, many of our customers are in the COVID-19 high-risk group. For these patients, their families, and their close contacts, fast and reliable diagnostics are critical to ensure everyday safety,” the Head of Spitzweg pharmacy, Gabor Perl, said. “PCR tests are the diagnostic gold standard for COVID-19. They provide high sensitivity and specificity. We are pleased to take part in this pilot project and now offer our high-risk-group customers access to a rapid PCR test with immediate results. We believe this is an opportunity for best-in-class healthcare delivery.” The pilot program’s COVID-19 rapid test, which is used for the positive detection of SARS-CoV-2 (COVID-19), is based on the reverse transcriptase-polymerase chain reaction for results. XPhyto is currently in talks and negotiations with distribution and wholesale partners, with a potential sales launch in Europe during Q2 2021. The company is not making any express or implied claims that its product can eliminate, cure or contain the COVID-19 pandemic. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• The Chinese SaaS market has been experiencing a boom, but even then, no dominant player has emerged
• Infobird is expanding its target market by transitioning to providing more standardized SaaS services to various enterprises across China
• IFBD is ideally positioned to capture the lion’s share of the SaaS market in China thanks to both intrinsic and extrinsic factors

The Chinese SaaS market is currently experiencing a boom – described as one of the fastest-growing in the world – and is expected to double by 2022, with the 2019 market size as the measure (https://ibn.fm/oE9Qd). This projection coincides with Howard Wang’s long-term outlook for the Chinese tech industry. Wang, the head of Greater China equities at JPMorgan Asset Management, recently told CNBC that although the near term is likely to be bumpy for companies in this space owing to regulatory clampdown aimed at curbing monopolistic behavior, the longer term holds great promise as Chinese tech companies have the potential to grow (https://ibn.fm/YXTzt). Thus, the Chinese tech market bodes well for Infobird (NASDAQ: IFBD), a leading SaaS provider that offers patented, innovative AI-powered, customer-engagement solutions in China. Infobird, which aims to capture the bulk of the market share within the SaaS space, is expanding its target market and rolling out standardized SaaS modules to service mid-to-large enterprises, as well as millions of small-to-medium-sized enterprises (“SMEs”) (https://ibn.fm/qCa0g). With the nature of the SaaS landscape in China providing tailwinds, IFBD appears ideally positioned to realize these goals. According to a NetworkNewsWire editorial (https://ibn.fm/Ab328), the Chinese SaaS market is highly fragmented. The top 10 vendors, for example, only hold a mere 35% of the market share, meaning no big market leader has emerged yet. In fact, the biggest player in this market has only managed to capture 7.2% of the market (https://ibn.fm/m2kv3). A look at the SaaS landscape points to the possible reasons why this is the case and, by extension, highlights why the conditions are favorable for IFBD to thrive. About 90% of companies in China are SMEs, and although they contribute approximately 60% to the country’s GDP, their revenue contributions to SaaS providers are small and less stable. The remaining 10% comprises the mid-to-large enterprises, which offer more stable revenue contributions to SaaS providers, but with a caveat. While SMEs do not have customization needs, the same cannot be said of mid-to-large-sized companies. And this presents a persistent problem that other SaaS companies have not yet quite figured out: striking a balance between standardization and customization. “Whoever can best solve this balance dilemma and quickly expand the market with standardized solutions will emerge as the next industry leader,” reads the editorial. This situation plays to IFBD’s strengths. Infobird supports innovation (as evidenced by its impressive list of intellectual property and the fact that 40% of its workforce are part of its R&D team, as of December last year), has extensive experience working with large organizations in China, and recently completed an IPO in which it raised $25 million (https://ibn.fm/BQE0J). “Now, leveraging its proficiency, R&D activities, and half of its IPO proceeds, Infobird is undergoing a transition to providing more standardized SaaS services to both mid-to-large enterprises and the millions of SMEs in various industries across China,” the editorial continues. Infobird intends to use its already developed standardized SaaS modules and its proprietary no-code development platform to more readily create new SaaS modules with preprogrammed microservices at extremely low cost and therefore quickly adapt to the changing market demands and opportunities. With these new standardized modules already proving valuable by helping both SMEs and mid-to-large enterprises generate more business opportunities, not to mention the fact that they are fast and easy to roll out – making quick scalability a possibility – IFBD appears to have struck a balance. Further, given that IFBD already has proven templates guiding the development of the new standardized modules, its approach and success thus far cannot be easily matched by competitors. These factors mean that Infobird will not only be able to expand its target market and roll out its standardized modules successfully, but also looks set to capture the lion’s share of the SaaS market. For more information, visit the company’s website at www.Infobird.com/en/index.html NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• The company is preparing to ship initial product order to exclusive UK distributor
• Packaging, flavor, price point all add up to TAAT’s nicotine- and tobacco-free experience coming out on top as the company expands across the Atlantic
• The company has developed TAAT, a tobacco- and nicotine-free alternative to traditional cigarettes available in Original, Smooth and Menthol varieties

As TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) prepares the first shipment of its flagship product — TAAT(TM) — to be distributed and sold in the United Kingdom, several elements of the proprietary product appear to offer the company significant competitive advantages in this market (https://ibn.fm/PYW6k). Packaging, flavor and price point all add up to TAAT’s nicotine- and tobacco-free experience coming out on top as the company expands across the Atlantic. “We are very excited about our impending entrance into the U.K. market and our advantageous product distinction on the shelf,” said TAAT CEO Setti Coscarella, upon announcing that the company had received a purchase order for €100,000, or approximately C$149,000, from a wholesaler in London, which will be the exclusive distributor of TAAT in the United Kingdom. “Anytime your product is visually outstanding from its competition, a lot of work is already done for you. As we continue to explore opportunities outside of the U.K., we recognize that the European Union presents a complicated regulatory network, with each member country implementing its own rules with respect to importation, packaging tariffs, and other factors. Interest in our product from legal-aged smokers in Europe has been overwhelming, and we will navigate the regulations on a country-by-country basis.” Coscarella is referring to TAAT’s distinctive packaging, which in any market is eye catching, but in the United Kingdom, where tobacco cigarettes are sold under strict “plain packaging” guidelines, TAAT’s ability to visually distinguish itself from competitors will be particularly striking. TAAT will be sold in the United Kingdom in colorful packaging similar to the current design found in markets in the United States, and the company anticipates it will realize a competitive advantage based on the unique appearance of its red, blue, and green color palette compared to the “drab dark-brown” packs of leading tobacco cigarettes as specifically mandated under U.K. law. In addition, since menthol tobacco cigarettes were officially banned in the United Kingdom more than a year ago, TAAT’s ability to offer a Menthol option, along with its Original and Smooth flavors, presents another powerful advantage. On May 20, 2020, the UK government banned menthol cigarettes, including capsule, click on, click & roll, crushball and dual menthol forms of smoking. This ban does not apply to TAAT products, which are formulated from a Beyond Nicotine(TM) base that contains no nicotine or tobacco. Finally, TAAT anticipates its product offering will sell at a much lower price point compared to the relatively high retail cost of tobacco cigarettes in the UK and Ireland. The company noted that, based on data from the World Health Organization (“WHO”), the prices of the most-sold brand of cigarettes (pack of 20) in international dollars were, on average, $13.58 in the United Kingdom and $14.95 in Ireland, compared to $6.86 in the United States. With a 14.1% tobacco use incidence rate among the United Kingdom’s legal-aged population and an incidence rate of approximately 20% among adults in Ireland, TAAT anticipates exciting opportunities — and reception— as it enters these markets. The cost advantage, packaging and flavor options, combined with the incidence rate of smokers, many whom are eagerly seeking for a nicotine-free, tobacco-free alternative, place the company — and its game-changing product — in a strong position. TAAT Global Alternatives has developed TAAT, a tobacco-free and nicotine-free alternative to traditional cigarettes available in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco, a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, visit the company’s websites at www.TryTAAT.com and www.TAATGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF